277 related articles for article (PubMed ID: 26621780)
1. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
2. Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Xie C; Lu H; Nomura A; Hanse EA; Forster CL; Parker JB; Linden MA; Karasch C; Hallstrom TC
Mol Cancer; 2015 Apr; 14():93. PubMed ID: 25907958
[TBL] [Abstract][Full Text] [Related]
3.
Blee AM; He Y; Yang Y; Ye Z; Yan Y; Pan Y; Ma T; Dugdale J; Kuehn E; Kohli M; Jimenez R; Chen Y; Xu W; Wang L; Huang H
Clin Cancer Res; 2018 Sep; 24(18):4551-4565. PubMed ID: 29844131
[No Abstract] [Full Text] [Related]
4. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
Hill R; Song Y; Cardiff RD; Van Dyke T
Cancer Res; 2005 Nov; 65(22):10243-54. PubMed ID: 16288012
[TBL] [Abstract][Full Text] [Related]
6.
Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
[TBL] [Abstract][Full Text] [Related]
7. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
8. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
[TBL] [Abstract][Full Text] [Related]
9. Tgfbr2 inactivation facilitates cellular plasticity and development of Pten-null prostate cancer.
Zhao W; Zhu Q; Tan P; Ajibade A; Long T; Long W; Li Q; Liu P; Ning B; Wang HY; Wang RF
J Mol Cell Biol; 2018 Aug; 10(4):316-330. PubMed ID: 29228234
[TBL] [Abstract][Full Text] [Related]
10. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
11. Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
Kwak MK; Johnson DT; Zhu C; Lee SH; Ye DW; Luong R; Sun Z
PLoS One; 2013; 8(1):e53476. PubMed ID: 23308230
[TBL] [Abstract][Full Text] [Related]
12. The role of tumor suppressor dysregulation in prostate cancer progression.
Dean JL; Knudsen KE
Curr Drug Targets; 2013 Apr; 14(4):460-71. PubMed ID: 23410128
[TBL] [Abstract][Full Text] [Related]
13. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
14. Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.
Bjerke GA; Yang CS; Frierson HF; Paschal BM; Wotton D
Oncogene; 2014 Jul; 33(28):3660-7. PubMed ID: 23995785
[TBL] [Abstract][Full Text] [Related]
15. Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging.
Yong C; Moose DL; Bannick N; Gutierrez WR; Vanneste M; Svensson R; Breheny P; Brown JA; Dodd RD; Cohen MB; Henry MD
PLoS One; 2020; 15(9):e0232807. PubMed ID: 32986721
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer.
Couto SS; Cao M; Duarte PC; Banach-Petrosky W; Wang S; Romanienko P; Wu H; Cardiff RD; Abate-Shen C; Cunha GR
Differentiation; 2009 Jan; 77(1):103-11. PubMed ID: 19281769
[TBL] [Abstract][Full Text] [Related]
17. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
18. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.
Kwon OJ; Zhang L; Wang J; Su Q; Feng Q; Zhang XH; Mani SA; Paulter R; Creighton CJ; Ittmann MM; Xin L
J Clin Invest; 2016 Jul; 126(7):2626-41. PubMed ID: 27294523
[TBL] [Abstract][Full Text] [Related]
19. Atg7 cooperates with Pten loss to drive prostate cancer tumor growth.
Santanam U; Banach-Petrosky W; Abate-Shen C; Shen MM; White E; DiPaola RS
Genes Dev; 2016 Feb; 30(4):399-407. PubMed ID: 26883359
[TBL] [Abstract][Full Text] [Related]
20. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
Ma X; Ziel-van der Made AC; Autar B; van der Korput HA; Vermeij M; van Duijn P; Cleutjens KB; de Krijger R; Krimpenfort P; Berns A; van der Kwast TH; Trapman J
Cancer Res; 2005 Jul; 65(13):5730-9. PubMed ID: 15994948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]